<VariationArchive VariationID="863227" VariationName="NM_000074.3(CD40LG):c.401del (p.Thr134fs)" VariationType="Deletion" Accession="VCV000863227" Version="8" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-06" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="849678" VariationID="863227">
      <GeneList>
        <Gene Symbol="CD40LG" FullName="CD40 ligand" GeneID="959" HGNC_ID="HGNC:11935" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq26.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="136648158" stop="136660390" display_start="136648158" display_stop="136660390" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="135730335" stop="135742548" display_start="135730335" display_stop="135742548" Strand="+" />
          </Location>
          <OMIM>300386</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CD40LG">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CD40LG">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000074.3(CD40LG):c.401del (p.Thr134fs)</Name>
      <CanonicalSPDI>NC_000023.11:136656409:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq26.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="136656410" stop="136656410" display_start="136656410" display_stop="136656410" variantLength="1" positionVCF="136656409" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="135738569" stop="135738569" display_start="135738569" display_stop="135738569" variantLength="1" positionVCF="135738568" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>T134fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_141" sequenceAccession="LRG_141">
            <Expression>LRG_141:g.13234del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_141t1" sequenceAccession="LRG_141t1">
            <Expression>LRG_141t1:c.401del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.135738569del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.135738569del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.136656410del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.136656410del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007280.1" sequenceAccession="NG_007280" sequenceVersion="1" change="g.13234del">
            <Expression>NG_007280.1:g.13234del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000074.3" sequenceAccession="NM_000074" sequenceVersion="3" change="c.401del" MANESelect="true">
            <Expression>NM_000074.3:c.401del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000065.1" sequenceAccession="NP_000065" sequenceVersion="1" change="p.Thr134fs">
            <Expression>NP_000065.1:p.Thr134fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2076119189" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000074.3(CD40LG):c.401del (p.Thr134fs) AND Hyper-IgM syndrome type 1" Accession="RCV001070147" Version="7">
        <ClassifiedConditionList TraitSetID="3084">
          <ClassifiedCondition DB="MedGen" ID="C0398689">Hyper-IgM syndrome type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-01-31" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-01-31" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">18805740</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8550833</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3084" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5326" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hyper IgM immunodeficiency, X-linked</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hyper-IgM syndrome type 1</ElementValue>
                <XRef ID="MONDO:0010626" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">X-linked hyper-IgM syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-IgM Immunodeficiency Syndrome, Type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with hyper IgM type 1</ElementValue>
                <XRef ID="Immunodeficiency+with+hyper+IgM+type+1/3776" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XHIM</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HIGM</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IHIS</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HIGM1</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">X-linked hyper IgM syndrome (HIGM1), a disorder of abnormal T- and B-cell function, is characterized by low serum concentrations of IgG, IgA, and IgE with normal or elevated serum concentrations of IgM. Mitogen proliferation may be normal, but NK- and T-cell cytotoxicity can be impaired. Antigen-specific responses are usually decreased or absent. Total numbers of B cells are normal but there is a marked reduction of class-switched memory B cells. Defective oxidative burst of both neutrophils and macrophages has been reported. The range of clinical findings varies, even within the same family. More than 50% of males with HIGM1 develop symptoms by age one year, and more than 90% are symptomatic by age four years. HIGM1 usually presents in infancy with recurrent upper- and lower-respiratory tract bacterial infections, opportunistic infections including Pneumocystis jirovecii pneumonia, and recurrent or protracted diarrhea that can be infectious or noninfectious and is associated with failure to thrive. Neutropenia is common; thrombocytopenia and anemia are less commonly seen. Autoimmune and/or inflammatory disorders (such as sclerosing cholangitis) as well as increased risk for neoplasms have been reported as medical complications of this disorder. Significant neurologic complications, often the result of a CNS infection, are seen in 5%-15% of affected males. Liver disease, a serious complication of HIGM1 once observed in more than 80% of affected males by age 20 years, may be decreasing with adequate screening and treatment of Cryptosporidium infection.</Attribute>
                <XRef ID="NBK1402" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="73" />
                <XRef ID="73" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301576</ID>
                <ID Source="BookShelf">NBK1402</ID>
              </Citation>
              <XRef ID="101088" DB="Orphanet" />
              <XRef ID="C0398689" DB="MedGen" />
              <XRef ID="MONDO:0010626" DB="MONDO" />
              <XRef Type="MIM" ID="308230" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2401025" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="8832336|MedGen:C0398689" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001235360" DateUpdated="2024-02-20" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8550833</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18805740</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the CD40LG protein. Other variant(s) that disrupt this region (p.Gln232*) have been determined to be pathogenic (PMID: 8550833, 18805740). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with CD40LG-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the CD40LG gene (p.Thr134Lysfs*15). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 128 amino acids of the CD40LG protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CD40LG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.135738569del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0398689" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2401025" TraitType="Disease" MappingType="XRef" MappingValue="C0398689" MappingRef="MedGen">
        <MedGen CUI="C0398689" Name="Hyper-IgM syndrome type 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

